Antimicrobial Studies of Cannabidiol as Biomaterials against superbug MRSA
Due to its limited treatment options, multi-drug resistant bacteria such as Gram-positive methicillin-resistant Staphylococcus aureus (MRSA) still remains a serious public health threat. The creation of new compelling antimicrobial materials, antibiotics and optional methodologies, which are successful against resistant microbes, is earnestly required. The legalization of cannabis in Canada has provided a new opportunity to investigate the antimicrobial studies of both extracts and individual cannabinoids.
This study investigates pure cannabidiol (CBD) isolated from Cannabis sativa by using a methodology of extraction, purification, characterization, and quantification of CBD. The shredded plant material was dissolved in ethanol, with the extract further purified using supercritical fluid chromatography (SFC) to obtain purified CBD. Product purity was confirmed by HPLC and NMR spectroscopy. CBD’s antibacterial activity on MRSA strain USA300 bacteria was studied using dilution series in liquid culture and disk diffusion assays to provide the minimum inhibitory concentration (MIC) and minimal bactericidal concentrations (MBC).
The results showed that CBD exhibited a significant bactericidal effect on MRSA with the MIC value of 2.5 µg/mL and MBC of 10 µg/mL. CBD powder form gave a higher antimicrobial activity than its oil form in terms of the inhibition zone. This study shows that CBD exhibits good antimicrobial impact against the MRSA strain showing its utility for enabling a new antibiotic free method for treating MRSA infections.
Keywords—CBD, antimicrobial activity, MRSA